Estimated disability-adjusted life years averted by long-term provision of long acting contraceptive methods in a Brazilian clinic

Human Reproduction

Volumn 29, Issue 10, 2014, Pages 2163-2170

  Bahamondes, Luis ^a   Bottura, Bruna F ^a   Bahamondes, M Valeria ^a   Gonçalves, Mayara P ^a   Correia, Vinicius M ^a   Espejo Arce, Ximena ^a   Sousa, Maria H ^a   Monteiro, Ilza ^a   Fernandes, Arlete ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Brazil; Contraceptive methods; Disability adjusted life years; Effectiveness; Long acting reversible contraceptives (LARCS)

Indexed keywords

MEDROXYPROGESTERONE ACETATE; CONTRACEPTIVE AGENT; LEVONORGESTREL; MEDROXYPROGESTERONE;

ABORTION; ADOLESCENT; ADULT; ARTICLE; BRAZIL; CHILD; CHILDHOOD MORTALITY; CONTRACEPTION; CONTRACEPTIVE BEHAVIOR; COPPER INTRAUTERINE DEVICE; DISABILITY; DISABILITY ADJUSTED LIFE YEAR; DRUG COST; DRUG IMPLANT; FAMILY PLANNING; FEMALE; FEMALE CONTRACEPTIVE DEVICE; HUMAN; LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM; LONG ACTING REVERSIBLE CONTRACEPTIVE METHOD; LONG TERM CARE; MATERNAL DEATH; MATERNAL MORBIDITY; MATERNAL MORTALITY; NORMAL HUMAN; PREGNANCY RATE; QUALITY OF LIFE; RETROSPECTIVE STUDY; INTRAUTERINE CONTRACEPTIVE DEVICE; PREGNANCY; PROCEDURES; QUALITY ADJUSTED LIFE YEAR; TIME; UNPLANNED PREGNANCY;

BRAZIL; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; FEMALE; HUMANS; INTRAUTERINE DEVICES, COPPER; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; MEDROXYPROGESTERONE; PREGNANCY; PREGNANCY, UNPLANNED; QUALITY-ADJUSTED LIFE YEARS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84930812524     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/deu191     Document Type: Article

References (42)

1. Abortionstatistics, England and Wales 2012. UKGovernment, Department of Health, 2013. https://www.gov. uk/government/collections/abortionstatistics-for-england-and-wales.
2. Aoun J, Dines VA, Stovall DW, Mete M, Nelson CB, Gomez-Lobo V. Effects of age, parity, and device type on complications and discontinuation of intrauterine devices. Obstet Gynecol 2014;123:585-592.
3. Bahamondes L, Faundes A, Sobreira-Lima B, Lui-Filho JF, Pecci P, Matera S. TCu 380A IUD: a reversible permanent contraceptive method in women over 35 years of age. Contraception 2005;72:337-341.
4. Blumenthal PD, Voedisch A, Gemzell-Danielsson K. Strategies to prevent unintended pregnancy: increasing use of long-acting reversible contraception. Hum Reprod Update 2011;17:121-137.
5. Blumenthal PD, Shah NM, Jain K, Saunders A, Clemente C, Lucas B, Jafa K, Eber M. Revitalizing long-acting reversible contraceptives in settings with high unmet need: a multicountry experience matching demand creation and service delivery. Contraception 2013;87:170-175.
6. Cleland J, Conde-Agudelo A, Peterson H, Ross J, Tsui A. Contraception and health. Lancet 2012;380:149-156.
7. Díaz J, Pinto Neto A, Díaz M, Marchi NM, Bahamondes L. Long-term evaluation of the clinical performance of the TCu200B and the TCu380A in Campinas, Brazil. Adv Contracept 1992a; 8:67-72.
8. Díaz J, Bahamondes L, Díaz M, Marchi N, Fauńdes A, Marini M. Evaluation of the performance of the copper T380A IUD up to ten years. Is this IUD a reversible but potentially permanent method? Adv Contracept 1992b; 8:275-280.
9. Eisenberg D, McNicholas C, Peipert JF. Cost as a barrier to long-acting reversible contraceptive (LARC) use in adolescents. J Adolesc Health 2013;52(4 Suppl):S59-S63.
10. Espey E, Ogburn T. Long-acting reversible contraceptives: intrauterine devices and the contraceptive implant. Obstet Gynecol 2011;117:705-719.
11. EstanislaudoAmaral MC, Hardy E, Hebling EM, Fauńdes A. Menstruationand amenorrhea: opinion of Brazilian women. Contraception 2005;72:157-161.
12. Etienne CF. Social determinants of health in the Americas. Rev Panam Salud Publica 2013;34:375-378.
13. Ferreira JM, Nunes FR, Modesto W, Gonçalves MP, Bahamondes L. Reasons for Brazilian women to switch from different contraceptives to long-acting reversible contraceptives. Contraception 2014;89:17-21.
14. Finer LB, Jerman J, Kavanaugh ML. Changes in use of long-acting contraceptive methods in the United States, 2007-2009. Fertil Steril 2012;98:893-897.
15. Information Please Database. Prevalence of contraceptive use in selected countries. Pearson Education, 2008. http://www.infoplease.com/ipa/A0193123.html (6 January 2014, date last accessed).
16. Jones RK, Jerman J. Abortion incidence and service availability in the United States, 2011. Perspect Sex Reprod Health 2014;46:3-14.
17. Jones J, Mosher W, Daniels K. Current contraceptive use in the United States, 2006-2010, and changes in patterns of use since 1995. National Health Statistics Reports, No. 60. Hyattsville, MD: National Center for Health Statistics, 2012. http://www.cdc.gov/nchs/data/nhsr/nhsr060.pdf.
18. Makuch MY, Osis MJ, Petta CA, de Pádua KS, Bahamondes L. Menstrual bleeding: perspective of Brazilian women. Contraception 2011;84:622-627.
19. Makuch MY, Duarte-Osis MJ, de Pádua KS, Petta C, Bahamondes L. Opinion and experience of Brazilian women regarding menstrual bleeding and use of combined oral contraceptives. Int J Gynaecol Obstet 2012;117:5-9.
20. Mavranezouli I, LARC Guideline Development Group. The cost-effectiveness of long-acting reversible contraceptive methodsinthe UK: analysis based on a decision-analytic model developed for a National Institute for Health and Clinical Excellence (NICE) clinical practice guideline. Hum Reprod 2008;23:1338-1345.
21. Meirik O, Farley TM, Sivin I. Safety and efficacy of levonorgestrel implant, intrauterine device, and sterilization. Obstet Gynecol 2001;97:539-547.
22. Mendes Ada C, Sá DA, Miranda GM, Lyra TM, Tavares RA. The public healthcare system in the context of Brazil's demographic transition: current and future demands. Cad Saude Publica 2012;28:955-964.
23. Nascimento R, Bahamondes L, Hidalgo M, Perrotti M, Espejo-Arce X, Petta CA. Users' perspectives on bleeding patterns after two years of levonorgestrel-releasing intrauterine system use. Drugs R D 2002;3:387-391.
24. Okie S. Fighting HIV-lessons from Brazil. N Engl J Med 2006;354:1977-1981.
25. Opinions Survey Report No. 41. Contraception and sexual health, 2008/09. London, UK: Office for National Statistics, 2009. www.opsi.gov. uk/click-use/index.htm.
26. Sivin I. Utility and drawbacks of continuous use of a copper T IUD for 20 years. Contraception 2007;75(6 Suppl):S70-S75.
27. Sivin I, Stern J, Coutinho E, Mattos CE, el Mahgoub S, Diaz S, Pavez M, Alvarez F, Brache V, Thevenin F et al. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380 Ag IUDS. Contraception 1991;44:473-480.
28. Sivin I, Diaz J, Alvarez F, Brache V, Diaz S, Pavez M, Stern J. Four-year experience in a randomized study of the Gyne T 380 Slimline and the Standard Gyne T 380 intrauterine copper devices. Contraception 1993;47:37-42.
29. Sivin I, Stern J, International Committee for Contraception Research (ICCR). Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). Fertil Steril 1994;61:70-77.
30. Sivin I, Mishell DR Jr, Diaz S, Biswas A, Alvarez F, Darney P, Holma P, Wan L, Brache V, Kiriwat O et al. Prolonged effectiveness of Norplant (R) capsule implants: a 7-year study. Contraception 2000;61:187-194.
31. Stover J, Ross J. Changes in the distribution of high-risk births associated with changes in contraceptive prevalence. BMC Public Health 2013;13(Suppl 3):S4.
32. Trussell J, Henry N, Hassan F, Prezioso A, Law A, Filonenko A. Burden of unintended pregnancy in the United States: potential savings with increased use of long-acting reversible contraception. Contraception 2013;87:154-161.
33. Tsui AO, McDonald-Mosley R, Burke AE. Family planning and the burden of unintended pregnancies. Epidemiol Rev 2010;32:152-174.
34. United Nations, Department of Economic and Social Affairs, Population Division. World Contraceptive Use 2012 (POP/DB/CP/Rev2012). United Nations, 2012. http://www.un.org/esa/population/publications/WCU2012/Data/UNPD-WCU2012-CP-Country%20Data%20Survey-Based.xls. (12 February 2014, date last accessed). http://www.mariestpoes.org/impact2; 2012. (15 March 2014, date last accessed).
35. Wellings K, Zhihong Z, Krentel A, Barrett G, Glasier A. Attitudes towards long-acting reversible methods of contraception in general practice in the UK. Contraception 2007;76:208-214.
36. Wilson EK, Fowler CI, Koo HP. Postpartum contraceptive use among adolescent mothers in seven states. J Adolesc Health 2013;52:278-283.
37. Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, Allsworth JE, Secura GM. Effectiveness of long-acting reversible contraception. N Engl J Med 2012;366:1998-2007.
38. World Health Organisation. Chapter3:Global burdenofdisease concept. In: Prüss-ü stün A, Campbell-Lendrum D, Corvalán C, Woodward A (eds). Introduction and Methods: Assessing the Environmental Burden of Disease at National and Local Levels. Geneva: WHO, 2003.
39. World Health Organisation. The Global Burden of Disease: 2004 Update. Geneva: WHO, 2008.
40. World Health Organisation, Department of Reproductive Health. Medical Eligibility Criteria for Contraceptive use. 2010. http://www.who.int/reproductivehealth/publications/family-planning/9789241563888/en/. (July 2013, date last accessed).
41. World Health Organisation. Trends in Maternal Mortality: 1990 to 2010 Estimates from WHO, UNICEF, UNFPA, and the World Bank. Geneva: WHO, 2012.
42. Xu X, Macaluso M, Ouyang L, Kulczycki A, Grosse SD. Revival of the intrauterine device: increased insertions among US women with employer-sponsored insurance, 2002-2008. Contraception 2012;85:155-159.